Form 4: Phathom Pharmaceuticals Director Michael Cola Receives Routine Equity Grants

Phathom Pharmaceuticals, Inc. Director Michael F. Cola was granted 10,500 Restricted Stock Units and 17,500 stock options as part of the company's non-employee director compensation program.

Summary

• Michael F. Cola, a Director of Phathom Pharmaceuticals, Inc. (PHAT), reported transactions on June 3, 2025.
• He acquired 10,500 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0.
• These RSUs are set to vest on the first anniversary of the grant date or the next annual meeting of stockholders, whichever occurs first, contingent on his continued service on the Board.
• Additionally, Mr. Cola acquired 17,500 Stock Options with an exercise price of $4.95.
• These options will also vest under the same conditions as the RSUs and have an expiration date of June 2, 2035.
• Both the RSU and option grants were made pursuant to the Issuer's Non-Employee Director Compensation Program.
• Following these transactions, Michael F. Cola beneficially owns 39,798 shares of Common Stock and 17,500 Stock Options.

Sentiment

Score: 7

Explanation: The filing reports routine equity grants to a non-employee director as part of a standard compensation program, which is generally viewed as a neutral to slightly positive event for aligning interests.

Positives

• The equity grants align the director's financial interests with those of the company's shareholders, encouraging long-term value creation.
• The grants are part of a standard, disclosed Non-Employee Director Compensation Program, indicating structured corporate governance.

Future Outlook

The vesting of both the Restricted Stock Units and stock options is contingent upon Michael F. Cola's continued service on the Board of Directors through the vesting date, which is the earlier of the first anniversary of the grant date or the next annual meeting of stockholders.

Industry Context

Equity grants to non-employee directors are a common practice across industries, including the pharmaceutical sector, to attract and retain qualified board members and align their interests with long-term company performance.

Comparison to Industry Standards

• The granting of Restricted Stock Units and stock options to non-employee directors is a standard component of compensation packages in publicly traded companies, particularly within the biotechnology and pharmaceutical industries, aimed at aligning director incentives with shareholder value creation.
• The vesting schedule tied to continued service and annual meetings is typical for such equity awards.

Corporate Governance

Related Party Transactions

• Equity grants to a non-employee director (Michael F. Cola) as part of the company's established Non-Employee Director Compensation Program.

Stakeholder Impact

• Shareholders: The equity grants are designed to align the director's long-term interests with those of the shareholders, potentially leading to better governance and strategic decisions aimed at increasing shareholder value.

Next Steps

• Vesting of the 10,500 Restricted Stock Units and 17,500 Stock Options will occur on the first anniversary of the grant date (June 3, 2026) or the next annual meeting of stockholders, whichever is earlier, subject to continued service.

Key Dates

Keywords

Phathom Pharmaceuticals, PHAT, Michael Cola, Director Compensation, Restricted Stock Units, RSU, Stock Options, Equity Grant, SEC Form 4, Insider Transaction